Once again, a major corporation picked a boutique over a Wall Street mega-bank to advise on its multi-billion dollar deal

Robert GreenhillREUTERS/Jeff ChristensenRobert Greenhill, Chairman and CEO of Greenhill & Co.

Once again, it looks like Wall Street’s biggest banks just missed out on one of the biggest deals of 2015.

On one side of the deal, projected to be worth about $US40 billion, is Teva Pharmaceuticals, which is aiming to buy its peer Mylan N.V. for $US82 per share in a cash-and-stock deal. Teva, according to a statement, is being advised by Greenhill & Co., a boutique bank that went public in 2004.

It isn’t yet clear who’s advising on the other side of the deal, but Centerview Partners has been an advisor to Mylan N.V. in the past, and as recently as summer 2014.

If that’s the case, it’s yet another big win for an advisor that has been taking a growing portion of big banks’ advisory fees, especially in 2015. And it’s part of a pattern of smaller banks displacing boutiques, especially on some big deals.

Representatives for Teva Pharmaceuticals did not immediately comment when contacted by Business Insider; Centerview did not immediately comment.

NOW WATCH: 6 little-known Excel shortcuts that will impress your boss

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.